CD274 and non-small cell lung carcinoma: In a clinical study, treatment of NSCLC patients with the combination of ipilimumab and nivolumab had an overall survival of 17.1 months, which was better than the overall survival of 13.9 months with chemotherapy alone (Table 1), and was independent of PD-L1 expression (Hellmann et al., 2019).